Brief: Inozyme Pharma Expects To Initiate A Pivotal Trial In Pediatric Patients With ABCC6 Deficiency In Q1 2025

Inozyme Pharma

08/04/2024 12:34

April 8 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM
ONGOING
PHASE 1/2 TRIALS OF INZ-701 IN ADULTS WITH ABCC6 DEFICIENCY
(PXE) AND ENPP1 DEFICIENCY
    * INOZYME PHARMA INC: FAVORABLE SAFETY, IMMUNOGENICITY AND
CLINICAL OUTCOME DATA WERE MAINTAINED THROUGH 48 WEEKS IN
COHORTS 1-3 IN ENPP1 DEFICIENCY
    * INOZYME PHARMA INC: FAVORABLE SAFETY AND IMMUNOGENICITY
PROFILE
IN ABCC6 DEFICIENCY
    * INOZYME PHARMA INC: INZ-701 WAS GENERALLY WELL TOLERATED
AND
EXHIBITED A FAVORABLE SAFETY PROFILE, WITH NO SERIOUS OR SEVERE
ADVERSE EVENTS
    * INOZYME PHARMA INC: EXPECTS TO INITIATE A PIVOTAL TRIAL IN
PEDIATRIC PATIENTS WITH ABCC6 DEFICIENCY IN Q1 2025

Source text for Eikon:  ID:nGNX7TwvMR 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))